PMC ID,Parameter,Reported numerical value,Unit,Bacterial species name,Bacterial strain(s),Source of isolates,Wild-type or mutant status,Biofilm / planktonic / mixed,Drug or chemical compound name(s),Drug amount/concentration with unit and time,Evidence - First Sentence of paragraph with numerical data,Title,Citation,,
PMC10060419,Minimum inhibitory concentration (MIC),3,mg/ml,Pseudomonas aeruginosa,ATCC 27853,PA 27853 was obtained from the international PA panel,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.","After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10060419,Minimum inhibitory concentration (MIC),3,mg/ml,Pseudomonas aeruginosa,PA1,Samples were obtained from the sputum of cystic fibrosis patients.,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.","After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10060419,Minimum inhibitory concentration (MIC),3,mg/ml,Pseudomonas aeruginosa,PA2,Samples were obtained from the sputum of cystic fibrosis patients.,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.","After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10060419,Minimum inhibitory concentration (MIC),3,mg/ml,Pseudomonas aeruginosa,PA3,Samples were obtained from the sputum of cystic fibrosis patients.,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.","After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10060419,Minimum inhibitory concentration (MIC),3,mg/ml,Pseudomonas aeruginosa,PA4,Samples were obtained from the sputum of cystic fibrosis patients.,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.","After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10060419,Minimum inhibitory concentration (MIC),3,mg/ml,Pseudomonas aeruginosa,PA5,Samples were obtained from the sputum of cystic fibrosis patients.,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.","After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10060419,Minimum inhibitory concentration (MIC),3,mg/ml,Pseudomonas aeruginosa,PA6,Samples were obtained from the sputum of cystic fibrosis patients.,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.","After a 24-h incubation period in aerobic conditions at 37 °C, turbidity was observed in the test tubes with 23.4 μg/ml–1.5 mg/ml ZnO NP concentrations in all PA strains, indicating bacterial growth. In test tubes with ZnO NP concentrations of 3 and 6 mg/ml, no turbidity was observed among all tested strains, indicating the inhibition of bacterial growth.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10060419,Minimum bactericidal concentration (MBC),6,mg/ml,Pseudomonas aeruginosa,ATCC 27853,PA 27853 was obtained from the international PA panel,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.","The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10060419,Minimum bactericidal concentration (MBC),6,mg/ml,Pseudomonas aeruginosa,PA1,Samples were obtained from the sputum of cystic fibrosis patients.,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.","The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10060419,Minimum bactericidal concentration (MBC),6,mg/ml,Pseudomonas aeruginosa,PA2,Samples were obtained from the sputum of cystic fibrosis patients.,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.","The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10060419,Minimum bactericidal concentration (MBC),6,mg/ml,Pseudomonas aeruginosa,PA3,Samples were obtained from the sputum of cystic fibrosis patients.,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.","The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10060419,Minimum bactericidal concentration (MBC),6,mg/ml,Pseudomonas aeruginosa,PA4,Samples were obtained from the sputum of cystic fibrosis patients.,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.","The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10060419,Minimum bactericidal concentration (MBC),6,mg/ml,Pseudomonas aeruginosa,PA5,Samples were obtained from the sputum of cystic fibrosis patients.,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.","The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10060419,Minimum bactericidal concentration (MBC),6,mg/ml,Pseudomonas aeruginosa,PA6,Samples were obtained from the sputum of cystic fibrosis patients.,NAN,NAN,Zinc Oxide nanoparticles (ZnO NPs),"The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.","The suspension from the tubes of 3 and 6 mg/ml was inoculated in a BHI agar plate and incubated for 24 h. There was no bacterial growth in the plate with 6 mg/ml, showing that it was bactericidal. Therefore, these results demonstrate that the MIC and MBC of ZnO NPs for all PA strains were successful at concentrations of 3 and 6 mg/ml, respectively.",The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation,"Al-Momani H, Al Balawi D, Hamed S, Albiss BA, Almasri M, AlGhawrie H, Ibrahim L, Al Balawi H, Al Haj Mahmoud S, Pearson J, Ward C. The impact of biosynthesized ZnO nanoparticles from Olea europaea (Common Olive) on Pseudomonas aeruginosa growth and biofilm formation. Sci Rep. 2023 Mar 29;13(1):5096. doi: 10.1038/s41598-023-32366-1. PMID: 36991258; PMCID: PMC10060419.",,
PMC10100964,NAN,NAN,NAN,NAN,NAN,NAN,NAN,NAN,NAN,NAN,NAN,Planktonic and Biofilm-Derived Pseudomonas aeruginosa Outer Membrane Vesicles Facilitate Horizontal Gene Transfer of Plasmid DNA,"Johnston EL, Zavan L, Bitto NJ, Petrovski S, Hill AF, Kaparakis-Liaskos M. Planktonic and Biofilm-Derived Pseudomonas aeruginosa Outer Membrane Vesicles Facilitate Horizontal Gene Transfer of Plasmid DNA. Microbiol Spectr. 2023 Mar 22;11(2):e0517922. doi: 10.1128/spectrum.05179-22. Epub ahead of print. PMID: 36946779; PMCID: PMC10100964.",,
PMC10174691,Growth rate,0.40 +/- 0.19,1/hr,Staphylococcus aureus,RN4220,NAN,NAN,NAN,NAN,NAN,"For simulations where growth rate (μ) was not varied, we estimated the growth rate of both bacterial species using the average growth rate found in the study (Figure 1B, Figure 3A, Figure 3F and S. aureus = 0.40 +/- 0.19; P. aeruginosa = 0.3 +/- 0.045).",Interactions between metabolism and growth can determine the co-existence of Staphylococcus aureus and Pseudomonas aeruginosa,"Pajon C, Fortoul MC, Diaz-Tang G, Marin Meneses E, Kalifa AR, Sevy E, Mariah T, Toscan B, Marcelin M, Hernandez DM, Marzouk MM, Lopatkin AJ, Eldakar OT, Smith RP. Interactions between metabolism and growth can determine the co-existence of Staphylococcus aureus and Pseudomonas aeruginosa. Elife. 2023 Apr 20;12:e83664. doi: 10.7554/eLife.83664. PMID: 37078696; PMCID: PMC10174691.",,
PMC10174691,Growth rate,0.3 +/- 0.045,1/hr,Pseudomonas aeruginosa,PA14,NAN,NAN,NAN,NAN,NAN,"For simulations where growth rate (μ) was not varied, we estimated the growth rate of both bacterial species using the average growth rate found in the study (Figure 1B, Figure 3A, Figure 3F and S. aureus = 0.40 +/- 0.19; P. aeruginosa = 0.3 +/- 0.045).",Interactions between metabolism and growth can determine the co-existence of Staphylococcus aureus and Pseudomonas aeruginosa,"Pajon C, Fortoul MC, Diaz-Tang G, Marin Meneses E, Kalifa AR, Sevy E, Mariah T, Toscan B, Marcelin M, Hernandez DM, Marzouk MM, Lopatkin AJ, Eldakar OT, Smith RP. Interactions between metabolism and growth can determine the co-existence of Staphylococcus aureus and Pseudomonas aeruginosa. Elife. 2023 Apr 20;12:e83664. doi: 10.7554/eLife.83664. PMID: 37078696; PMCID: PMC10174691.",,
PMC10190592,Minimum inhibitory concentration (MIC),0.25,mg/L,Staphylococcus aureus,ATCC 29213,NAN,parent strain,NAN,ciprofloxacin,0.25 mg/L,"The MIC values for the parent strain of Staphylococcus aureus ATCC 29213 were as follows: 0.25 mg/L for ciprofloxacin, 2 mg/L for linezolid, and 3.12 mg/L for novel benzosiloxaborole No37.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Minimum inhibitory concentration (MIC),2,mg/L,Staphylococcus aureus,ATCC 29213,NAN,parent strain,NAN,linezolid,2 mg/L,"The MIC values for the parent strain of Staphylococcus aureus ATCC 29213 were as follows: 0.25 mg/L for ciprofloxacin, 2 mg/L for linezolid, and 3.12 mg/L for novel benzosiloxaborole No37.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Minimum inhibitory concentration (MIC),3.12,mg/L,Staphylococcus aureus,ATCC 29213,NAN,parent strain,NAN,novel benzosiloxaborole No37,3.12 mg/L,"The MIC values for the parent strain of Staphylococcus aureus ATCC 29213 were as follows: 0.25 mg/L for ciprofloxacin, 2 mg/L for linezolid, and 3.12 mg/L for novel benzosiloxaborole No37.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Frequency of spontaneous mutant selection (FSMS),5.5 × 10−9,NAN,Staphylococcus aureus,ATCC 29213,NAN,single-step resistant mutants,NAN,ciprofloxacin,"the 2-, 4-, and 8-mg/L concentrations","In the case of ciprofloxacin, the dense bacterial lawn was detected at concentrations up to 0.5 mg/L (2×MIC), the colony lawn with uncountable colonies at the concentration of 1 mg/L (4×MIC), and countable colonies were detected at every higher concentration.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Frequency of spontaneous mutant selection (FSMS),6 × 10−11,NAN,Staphylococcus aureus,ATCC 29213,NAN,single-step resistant mutants,NAN,ciprofloxacin,"the 2-, 4-, and 8-mg/L concentrations","In the case of ciprofloxacin, the dense bacterial lawn was detected at concentrations up to 0.5 mg/L (2×MIC), the colony lawn with uncountable colonies at the concentration of 1 mg/L (4×MIC), and countable colonies were detected at every higher concentration.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Frequency of spontaneous mutant selection (FSMS),4.5 × 10−11,NAN,Staphylococcus aureus,ATCC 29213,NAN,single-step resistant mutants,NAN,ciprofloxacin,"the 2-, 4-, and 8-mg/L concentrations","In the case of ciprofloxacin, the dense bacterial lawn was detected at concentrations up to 0.5 mg/L (2×MIC), the colony lawn with uncountable colonies at the concentration of 1 mg/L (4×MIC), and countable colonies were detected at every higher concentration.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Frequency of spontaneous mutant selection (FSMS),>3 × 10−8,NAN,Staphylococcus aureus,ATCC 29213,NAN,single-step resistant mutants,NAN,linezolid,2 mg/L (1×MIC),"Visual screening of the linezolid A-series plates only revealed a dense, noncolony lawn, slightly thinner on the three highest concentrations tested.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Frequency of spontaneous mutant selection (FSMS),<2 × 10−11,NAN,Staphylococcus aureus,ATCC 29213,NAN,single-step resistant mutants,NAN,linezolid,4 mg/L and above (≥2×MIC),"Visual screening of the linezolid A-series plates only revealed a dense, noncolony lawn, slightly thinner on the three highest concentrations tested.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Frequency of spontaneous mutant selection (FSMS),>3 × 10−8,NAN,Staphylococcus aureus,ATCC 29213,NAN,single-step resistant mutants,NAN,compound No37,50 mg/L (16×MIC),"The aMRTest was also required to determine the FSMS values for different concentrations of compound No37, as only a dense, noncolony lawn was observed on all A-series plates, regardless of the concentration.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Frequency of spontaneous mutant selection (FSMS),<2 × 10−11,NAN,Staphylococcus aureus,ATCC 29213,NAN,single-step resistant mutants,NAN,compound No37,"100 mg/L, 32×MIC","The aMRTest was also required to determine the FSMS values for different concentrations of compound No37, as only a dense, noncolony lawn was observed on all A-series plates, regardless of the concentration.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Mutant prevention concentration (MPC) – 10^10,> 8,mg/L,Staphylococcus aureus,ATCC 29213,NAN,single-step resistant mutants,NAN,ciprofloxacin,8 mg/L (32×MIC),"In the case of ciprofloxacin, as mutants were also detected at the highest tested concentration of 8 mg/L (32×MIC), the MPC1010 value was estimated as being above 8 mg/L (>32×MIC).","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Dominant mutant prevention concentration (MPC-D) – 10^10,4,mg/L,Staphylococcus aureus,ATCC 29213,NAN,single-step resistant mutants,NAN,ciprofloxacin,4 mg/L (16×MIC),"In the case of ciprofloxacin, as mutants were also detected at the highest tested concentration of 8 mg/L (32×MIC), the MPC1010 value was estimated as being above 8 mg/L (>32×MIC).","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Mutant prevention concentration (MPC) – 10^10,4,mg/L,Staphylococcus aureus,ATCC 29213,NAN,single-step resistant mutants,NAN,linezolid,4 mg/L (2×MIC),"On the contrary, when linezolid and compound No37 were tested, a visual assessment of mutant presence on the plates was impossible: only a gradually fading lawn was observed on all A-series plates with linezolid, while a dense lawn was present on all plates for compound No37, including the highest tested concentration.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Dominant mutant prevention concentration (MPC-D) – 10^10,4,mg/L,Staphylococcus aureus,ATCC 29213,NAN,single-step resistant mutants,NAN,linezolid,4 mg/L of linezolid,"On the contrary, when linezolid and compound No37 were tested, a visual assessment of mutant presence on the plates was impossible: only a gradually fading lawn was observed on all A-series plates with linezolid, while a dense lawn was present on all plates for compound No37, including the highest tested concentration.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Mutant prevention concentration (MPC) – 10^10,100,mg/L,Staphylococcus aureus,ATCC 29213,NAN,single-step resistant mutants,NAN,compound No37,100 mg/L (32×MIC),"On the contrary, when linezolid and compound No37 were tested, a visual assessment of mutant presence on the plates was impossible: only a gradually fading lawn was observed on all A-series plates with linezolid, while a dense lawn was present on all plates for compound No37, including the highest tested concentration.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Dominant mutant prevention concentration (MPC-D) – 10^10,100,mg/L,Staphylococcus aureus,ATCC 29213,NAN,single-step resistant mutants,NAN,compound No37,100 mg/L of compound No37,"On the contrary, when linezolid and compound No37 were tested, a visual assessment of mutant presence on the plates was impossible: only a gradually fading lawn was observed on all A-series plates with linezolid, while a dense lawn was present on all plates for compound No37, including the highest tested concentration.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Dominant mutant prevention concentration (MPC-D) – 10^10,2,mg/L,Staphylococcus aureus,ATCC 29213,NAN,resistant mutants,NAN,ciprofloxacin,2 mg/L (8×MIC),"In the case of ciprofloxacin on B-series plates, a dense lawn was observed at 0.25 mg/L (1×MIC), an uncountable colony lawn at 0.5 mg/L (2×MIC), and 65 colonies were detected at 1 mg/L (4×MIC).","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Inferior mutant prevention concentration (MPC-F) – 10^10,8,mg/L,Staphylococcus aureus,ATCC 29213,NAN,resistant mutants,NAN,ciprofloxacin,8 mg/L (32×MIC) of ciprofloxacin,"In the case of ciprofloxacin on B-series plates, a dense lawn was observed at 0.25 mg/L (1×MIC), an uncountable colony lawn at 0.5 mg/L (2×MIC), and 65 colonies were detected at 1 mg/L (4×MIC).","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Dominant mutant prevention concentration (MPC-D) – 10^10,4,mg/L,Staphylococcus aureus,ATCC 29213,NAN,NAN,NAN,linezolid,4 mg/L,"On B- and C-series linezolid plates, a dense lawn was observed at 2 mg/L (1×MIC), while at 4 mg/L (2×MIC) a thicker lawn, a semi-lawn, and a dense lawn, respectively.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Inferior mutant prevention concentration (MPC-F) – 10^10,4,mg/L,Staphylococcus aureus,ATCC 29213,NAN,NAN,NAN,linezolid,4 mg/L,"On B- and C-series linezolid plates, a dense lawn was observed at 2 mg/L (1×MIC), while at 4 mg/L (2×MIC) a thicker lawn, a semi-lawn, and a dense lawn, respectively.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Dominant mutant prevention concentration (MPC-D) – 10^10,100,mg/L,Staphylococcus aureus,ATCC 29213,NAN,obtained resistant mutants,NAN,compound No37,100 mg/L (32×MIC),"On B-series plates with compound No37, a dense lawn was visible up to 6.25 mg/L (2×MIC), while a colony lawn from 12.5 to 50 mg/L (4 to 16×MIC).","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Inferior mutant prevention concentration (MPC-F) – 10^10,100,mg/L,Staphylococcus aureus,ATCC 29213,NAN,obtained resistant mutants,NAN,compound No37,100 mg/L,"On B-series plates with compound No37, a dense lawn was visible up to 6.25 mg/L (2×MIC), while a colony lawn from 12.5 to 50 mg/L (4 to 16×MIC).","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Mutant selection window (MSW),1 to 2,×MIC,Staphylococcus aureus,ATCC 29213,NAN,NAN,NAN,linezolid,NAN,"Overall, linezolid had the narrowest ranges of MSWs, MSW-Ds, and MSW-Fs.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Dominant mutant selection window (MSW-D),1 to 2,×MIC,Staphylococcus aureus,ATCC 29213,NAN,NAN,NAN,linezolid,NAN,"Overall, linezolid had the narrowest ranges of MSWs, MSW-Ds, and MSW-Fs.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Inferior mutant selection window (MSW-F),1 to 2,×MIC,Staphylococcus aureus,ATCC 29213,NAN,NAN,NAN,linezolid,NAN,"Overall, linezolid had the narrowest ranges of MSWs, MSW-Ds, and MSW-Fs.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Mutant selection window (MSW),1 to 32,×MIC,Staphylococcus aureus,ATCC 29213,NAN,NAN,NAN,compound No37,NAN,"Overall, linezolid had the narrowest ranges of MSWs, MSW-Ds, and MSW-Fs. Regardless of the method, all of the above-mentioned parameters ranged between 1 and 2×MIC. Also, for compound No37, the MSW, MSW-Ds, and MSW-F had the same range of 1 to 32×MIC.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Dominant mutant selection window (MSW-D),1 to 32,×MIC,Staphylococcus aureus,ATCC 29213,NAN,NAN,NAN,compound No37,NAN,"Overall, linezolid had the narrowest ranges of MSWs, MSW-Ds, and MSW-Fs. Regardless of the method, all of the above-mentioned parameters ranged between 1 and 2×MIC. Also, for compound No37, the MSW, MSW-Ds, and MSW-F had the same range of 1 to 32×MIC.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Inferior mutant selection window (MSW-F),1 to 32,×MIC,Staphylococcus aureus,ATCC 29213,NAN,NAN,NAN,compound No37,NAN,"Overall, linezolid had the narrowest ranges of MSWs, MSW-Ds, and MSW-Fs. Regardless of the method, all of the above-mentioned parameters ranged between 1 and 2×MIC. Also, for compound No37, the MSW, MSW-Ds, and MSW-F had the same range of 1 to 32×MIC.","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Dominant mutant selection window (MSW-D) – 10^10,1 to 8,×MIC,Staphylococcus aureus,ATCC 29213,NAN,NAN,NAN,ciprofloxacin,NAN,"Overall, linezolid had the narrowest ranges of MSWs, MSW-Ds, and MSW-Fs. Regardless of the method, all of the above-mentioned parameters ranged between 1 and 2×MIC. Also, for compound No37, the MSW, MSW-Ds, and MSW-F had the same range of 1 to 32×MIC. In the case of ciprofloxacin, the narrowest range had the MSW-D1010 determined in the BM (1 to 8×MIC), while the MSW-D1010 determined in the AM was broader, ranging up to 4 mg/L (16×MIC), and the MSW-F1010 ranged up to 8 mg/L (32×MIC).","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Dominant mutant selection window (MSW-D) – 10^10,4,mg/L,Staphylococcus aureus,ATCC 29213,NAN,NAN,NAN,ciprofloxacin,4 mg/L (16×MIC),"Overall, linezolid had the narrowest ranges of MSWs, MSW-Ds, and MSW-Fs. Regardless of the method, all of the above-mentioned parameters ranged between 1 and 2×MIC. Also, for compound No37, the MSW, MSW-Ds, and MSW-F had the same range of 1 to 32×MIC. In the case of ciprofloxacin, the narrowest range had the MSW-D1010 determined in the BM (1 to 8×MIC), while the MSW-D1010 determined in the AM was broader, ranging up to 4 mg/L (16×MIC), and the MSW-F1010 ranged up to 8 mg/L (32×MIC).","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Inferior mutant selection window (MSW-F) – 10^10,8,mg/L,Staphylococcus aureus,ATCC 29213,NAN,NAN,NAN,ciprofloxacin,8 mg/L (32×MIC),"Overall, linezolid had the narrowest ranges of MSWs, MSW-Ds, and MSW-Fs. Regardless of the method, all of the above-mentioned parameters ranged between 1 and 2×MIC. Also, for compound No37, the MSW, MSW-Ds, and MSW-F had the same range of 1 to 32×MIC. In the case of ciprofloxacin, the narrowest range had the MSW-D1010 determined in the BM (1 to 8×MIC), while the MSW-D1010 determined in the AM was broader, ranging up to 4 mg/L (16×MIC), and the MSW-F1010 ranged up to 8 mg/L (32×MIC).","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10190592,Mutant selection window (MSW) – 10^10,> 8,mg/L,Staphylococcus aureus,ATCC 29213,NAN,NAN,NAN,ciprofloxacin,8 mg/L (>32×MIC),"Overall, linezolid had the narrowest ranges of MSWs, MSW-Ds, and MSW-Fs. Regardless of the method, all of the above-mentioned parameters ranged between 1 and 2×MIC. Also, for compound No37, the MSW, MSW-Ds, and MSW-F had the same range of 1 to 32×MIC. In the case of ciprofloxacin, the narrowest range had the MSW-D1010 determined in the BM (1 to 8×MIC), while the MSW-D1010 determined in the AM was broader, ranging up to 4 mg/L (16×MIC), and the MSW-F1010 ranged up to 8 mg/L (32×MIC). The upper limit of the MSW1010 for ciprofloxacin was above the highest tested concentration of 8 mg/L (>32×MIC).","Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window—a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds","Krajewska J, Tyski S, Laudy AE. Mutant Prevention Concentration, Frequency of Spontaneous Mutant Selection, and Mutant Selection Window-a New Approach to the In Vitro Determination of the Antimicrobial Potency of Compounds. Antimicrob Agents Chemother. 2023 May 17;67(5):e0137322. doi: 10.1128/aac.01373-22. Epub 2023 Apr 6. PMID: 37022162; PMCID: PMC10190592.",,
PMC10315054,Hill factor,Between 0.8 and 0.97,NAN,Pseudomonas aeruginosa,CRPA-45,NAN,resistant to carbapenem and produces biofilm,biofilm,ceftazidime,"0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC; overnight incubated","Recorded data concerning the anti-biofilm of the single agent was used to calculate the EC50, area under the curve (AUC), and Hill factor of each antibiotic. Data were presented in a sigmoidal inhibitory Emax model. The sigmoidal Emax exhibited close-fitting to the data, where the recorded R2 value was in the range between 0.77 and 0.99 as shown in Fig. 1. Assessment of the anti-biofilm potential of each antibiotic using different concentrations equivalent to 0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC revealed statistically significant superior anti-biofilm potential in the case of colistin followed by gentamicin and meropenem, while the least anti-biofilm activity was observed post-treatment with ceftazidime (p < 0.05). The EC50 and AUC were determined for each antibiotic. Hill factor values lying in a range between 0.8 and 0.97 reveal a strong correlation between the concentrations of the tested antimicrobials and their subsequent anti-biofilm potentials (Table 2).",Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm,"Badawy MSEM, Elkhatib WF, Shebl RI. Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm. Ann Clin Microbiol Antimicrob. 2023 Jul 2;22(1):53. doi: 10.1186/s12941-023-00597-9. PMID: 37394468; PMCID: PMC10315054.",,
PMC10315054,Hill factor,Between 0.8 and 0.97,NAN,Pseudomonas aeruginosa,CRPA-45,NAN,resistant to carbapenem and produces biofilm,biofilm,colistin,"0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC; overnight incubated","Recorded data concerning the anti-biofilm of the single agent was used to calculate the EC50, area under the curve (AUC), and Hill factor of each antibiotic. Data were presented in a sigmoidal inhibitory Emax model. The sigmoidal Emax exhibited close-fitting to the data, where the recorded R2 value was in the range between 0.77 and 0.99 as shown in Fig. 1. Assessment of the anti-biofilm potential of each antibiotic using different concentrations equivalent to 0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC revealed statistically significant superior anti-biofilm potential in the case of colistin followed by gentamicin and meropenem, while the least anti-biofilm activity was observed post-treatment with ceftazidime (p < 0.05). The EC50 and AUC were determined for each antibiotic. Hill factor values lying in a range between 0.8 and 0.97 reveal a strong correlation between the concentrations of the tested antimicrobials and their subsequent anti-biofilm potentials (Table 2).",Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm,"Badawy MSEM, Elkhatib WF, Shebl RI. Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm. Ann Clin Microbiol Antimicrob. 2023 Jul 2;22(1):53. doi: 10.1186/s12941-023-00597-9. PMID: 37394468; PMCID: PMC10315054.",,
PMC10315054,Hill factor,Between 0.8 and 0.97,NAN,Pseudomonas aeruginosa,CRPA-45,NAN,resistant to carbapenem and produces biofilm,biofilm,gentamicin,"0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC; overnight incubated","Recorded data concerning the anti-biofilm of the single agent was used to calculate the EC50, area under the curve (AUC), and Hill factor of each antibiotic. Data were presented in a sigmoidal inhibitory Emax model. The sigmoidal Emax exhibited close-fitting to the data, where the recorded R2 value was in the range between 0.77 and 0.99 as shown in Fig. 1. Assessment of the anti-biofilm potential of each antibiotic using different concentrations equivalent to 0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC revealed statistically significant superior anti-biofilm potential in the case of colistin followed by gentamicin and meropenem, while the least anti-biofilm activity was observed post-treatment with ceftazidime (p < 0.05). The EC50 and AUC were determined for each antibiotic. Hill factor values lying in a range between 0.8 and 0.97 reveal a strong correlation between the concentrations of the tested antimicrobials and their subsequent anti-biofilm potentials (Table 2).",Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm,"Badawy MSEM, Elkhatib WF, Shebl RI. Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm. Ann Clin Microbiol Antimicrob. 2023 Jul 2;22(1):53. doi: 10.1186/s12941-023-00597-9. PMID: 37394468; PMCID: PMC10315054.",,
PMC10315054,Hill factor,Between 0.8 and 0.97,NAN,Pseudomonas aeruginosa,CRPA-45,NAN,resistant to carbapenem and produces biofilm,biofilm,meropenem,"0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC; overnight incubated","Recorded data concerning the anti-biofilm of the single agent was used to calculate the EC50, area under the curve (AUC), and Hill factor of each antibiotic. Data were presented in a sigmoidal inhibitory Emax model. The sigmoidal Emax exhibited close-fitting to the data, where the recorded R2 value was in the range between 0.77 and 0.99 as shown in Fig. 1. Assessment of the anti-biofilm potential of each antibiotic using different concentrations equivalent to 0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC revealed statistically significant superior anti-biofilm potential in the case of colistin followed by gentamicin and meropenem, while the least anti-biofilm activity was observed post-treatment with ceftazidime (p < 0.05). The EC50 and AUC were determined for each antibiotic. Hill factor values lying in a range between 0.8 and 0.97 reveal a strong correlation between the concentrations of the tested antimicrobials and their subsequent anti-biofilm potentials (Table 2).",Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm,"Badawy MSEM, Elkhatib WF, Shebl RI. Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm. Ann Clin Microbiol Antimicrob. 2023 Jul 2;22(1):53. doi: 10.1186/s12941-023-00597-9. PMID: 37394468; PMCID: PMC10315054.",,
PMC10315054,Hill factor,Between 0.8 and 0.97,NAN,Pseudomonas aeruginosa,CRPA-47,NAN,resistant to carbapenem and produces biofilm,biofilm,ceftazidime,"0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC; overnight incubated","Recorded data concerning the anti-biofilm of the single agent was used to calculate the EC50, area under the curve (AUC), and Hill factor of each antibiotic. Data were presented in a sigmoidal inhibitory Emax model. The sigmoidal Emax exhibited close-fitting to the data, where the recorded R2 value was in the range between 0.77 and 0.99 as shown in Fig. 1. Assessment of the anti-biofilm potential of each antibiotic using different concentrations equivalent to 0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC revealed statistically significant superior anti-biofilm potential in the case of colistin followed by gentamicin and meropenem, while the least anti-biofilm activity was observed post-treatment with ceftazidime (p < 0.05). The EC50 and AUC were determined for each antibiotic. Hill factor values lying in a range between 0.8 and 0.97 reveal a strong correlation between the concentrations of the tested antimicrobials and their subsequent anti-biofilm potentials (Table 2).",Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm,"Badawy MSEM, Elkhatib WF, Shebl RI. Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm. Ann Clin Microbiol Antimicrob. 2023 Jul 2;22(1):53. doi: 10.1186/s12941-023-00597-9. PMID: 37394468; PMCID: PMC10315054.",,
PMC10315054,Hill factor,Between 0.8 and 0.97,NAN,Pseudomonas aeruginosa,CRPA-47,NAN,resistant to carbapenem and produces biofilm,biofilm,colistin,"0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC; overnight incubated","Recorded data concerning the anti-biofilm of the single agent was used to calculate the EC50, area under the curve (AUC), and Hill factor of each antibiotic. Data were presented in a sigmoidal inhibitory Emax model. The sigmoidal Emax exhibited close-fitting to the data, where the recorded R2 value was in the range between 0.77 and 0.99 as shown in Fig. 1. Assessment of the anti-biofilm potential of each antibiotic using different concentrations equivalent to 0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC revealed statistically significant superior anti-biofilm potential in the case of colistin followed by gentamicin and meropenem, while the least anti-biofilm activity was observed post-treatment with ceftazidime (p < 0.05). The EC50 and AUC were determined for each antibiotic. Hill factor values lying in a range between 0.8 and 0.97 reveal a strong correlation between the concentrations of the tested antimicrobials and their subsequent anti-biofilm potentials (Table 2).",Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm,"Badawy MSEM, Elkhatib WF, Shebl RI. Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm. Ann Clin Microbiol Antimicrob. 2023 Jul 2;22(1):53. doi: 10.1186/s12941-023-00597-9. PMID: 37394468; PMCID: PMC10315054.",,
PMC10315054,Hill factor,Between 0.8 and 0.97,NAN,Pseudomonas aeruginosa,CRPA-47,NAN,resistant to carbapenem and produces biofilm,biofilm,gentamicin,"0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC; overnight incubated","Recorded data concerning the anti-biofilm of the single agent was used to calculate the EC50, area under the curve (AUC), and Hill factor of each antibiotic. Data were presented in a sigmoidal inhibitory Emax model. The sigmoidal Emax exhibited close-fitting to the data, where the recorded R2 value was in the range between 0.77 and 0.99 as shown in Fig. 1. Assessment of the anti-biofilm potential of each antibiotic using different concentrations equivalent to 0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC revealed statistically significant superior anti-biofilm potential in the case of colistin followed by gentamicin and meropenem, while the least anti-biofilm activity was observed post-treatment with ceftazidime (p < 0.05). The EC50 and AUC were determined for each antibiotic. Hill factor values lying in a range between 0.8 and 0.97 reveal a strong correlation between the concentrations of the tested antimicrobials and their subsequent anti-biofilm potentials (Table 2).",Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm,"Badawy MSEM, Elkhatib WF, Shebl RI. Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm. Ann Clin Microbiol Antimicrob. 2023 Jul 2;22(1):53. doi: 10.1186/s12941-023-00597-9. PMID: 37394468; PMCID: PMC10315054.",,
PMC10315054,Hill factor,Between 0.8 and 0.97,NAN,Pseudomonas aeruginosa,CRPA-47,NAN,resistant to carbapenem and produces biofilm,biofilm,meropenem,"0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC; overnight incubated","Recorded data concerning the anti-biofilm of the single agent was used to calculate the EC50, area under the curve (AUC), and Hill factor of each antibiotic. Data were presented in a sigmoidal inhibitory Emax model. The sigmoidal Emax exhibited close-fitting to the data, where the recorded R2 value was in the range between 0.77 and 0.99 as shown in Fig. 1. Assessment of the anti-biofilm potential of each antibiotic using different concentrations equivalent to 0.25, 0.5, 1, 2, 4, 16, 32, and 64 times MBIC revealed statistically significant superior anti-biofilm potential in the case of colistin followed by gentamicin and meropenem, while the least anti-biofilm activity was observed post-treatment with ceftazidime (p < 0.05). The EC50 and AUC were determined for each antibiotic. Hill factor values lying in a range between 0.8 and 0.97 reveal a strong correlation between the concentrations of the tested antimicrobials and their subsequent anti-biofilm potentials (Table 2).",Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm,"Badawy MSEM, Elkhatib WF, Shebl RI. Mathematical pharmacodynamic modeling for antimicrobial assessment of ceftazidime/colistin versus gentamicin/meropenem combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm. Ann Clin Microbiol Antimicrob. 2023 Jul 2;22(1):53. doi: 10.1186/s12941-023-00597-9. PMID: 37394468; PMCID: PMC10315054.",,
PMC10583683,Minimum inhibitory concentration (MIC),8,mg/L,Pseudomonas aeruginosa,NAN,NAN,MDR IMI-resistant,NAN,imipenem (IMI),MIC of 8 mg/L,"A 58-year-old female patient, under chemotherapy for breast cancer, developed a catheter-related bacteremia.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),1,mg/L,Pseudomonas aeruginosa,PaS,NAN,susceptible to C/T,NAN,ceftolozane/tazobactam (C/T),an MIC equal to 1 mg/L,"A 58-year-old female patient, under chemotherapy for breast cancer, developed a catheter-related bacteremia.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),32,mg/L,Pseudomonas aeruginosa,PaR,blood cultures,C/T resistant but IMI susceptible,NAN,ceftolozane/tazobactam (C/T),MIC equal to 32 mg/L,"A 58-year-old female patient, under chemotherapy for breast cancer, developed a catheter-related bacteremia.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),1,mg/L,Pseudomonas aeruginosa,PaR,blood cultures,C/T resistant but IMI susceptible,NAN,imipenem (IMI),"1 mg/L for C/T and IMI, respectively","A 58-year-old female patient, under chemotherapy for breast cancer, developed a catheter-related bacteremia.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),0.25,mg/L,Pseudomonas aeruginosa,PAO1-AmpCG183D,NAN,single mutation,NAN,ceftolozane/tazobactam (C/T),MIC = 0.25 mg/L,"C/T MIC values of PAO1-AmpCG183D and PAO1-AmpDH157Y were identical to that of PAO1 (MIC = 0.25 mg/L), while that of the PAO1 double mutant (PAO1-AmpCG183D/AmpDH157Y) was increased eightfold (MIC = 2 mg/L).",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),0.25,mg/L,Pseudomonas aeruginosa,PAO1-AmpDH157Y,NAN,single mutation,NAN,ceftolozane/tazobactam (C/T),MIC = 0.25 mg/L,"C/T MIC values of PAO1-AmpCG183D and PAO1-AmpDH157Y were identical to that of PAO1 (MIC = 0.25 mg/L), while that of the PAO1 double mutant (PAO1-AmpCG183D/AmpDH157Y) was increased eightfold (MIC = 2 mg/L).",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),0.25,mg/L,Pseudomonas aeruginosa,PAO1,NAN,reference strain,NAN,ceftolozane/tazobactam (C/T),MIC = 0.25 mg/L,"C/T MIC values of PAO1-AmpCG183D and PAO1-AmpDH157Y were identical to that of PAO1 (MIC = 0.25 mg/L), while that of the PAO1 double mutant (PAO1-AmpCG183D/AmpDH157Y) was increased eightfold (MIC = 2 mg/L).",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),2,mg/L,Pseudomonas aeruginosa,PAO1-AmpCG183D/AmpDH157Y,NAN,double mutations,NAN,ceftolozane/tazobactam (C/T),MIC = 2 mg/L,"C/T MIC values of PAO1-AmpCG183D and PAO1-AmpDH157Y were identical to that of PAO1 (MIC = 0.25 mg/L), while that of the PAO1 double mutant (PAO1-AmpCG183D/AmpDH157Y) was increased eightfold (MIC = 2 mg/L).",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),1,mg/L,Pseudomonas aeruginosa,PaR-AmpCPaS/AmpDPaS,NAN,double reverted PaR isolate,NAN,ceftolozane/tazobactam (C/T),MIC = 1 mg/L,"C/T MIC values of PAO1-AmpCG183D and PAO1-AmpDH157Y were identical to that of PAO1 (MIC = 0.25 mg/L), while that of the PAO1 double mutant (PAO1-AmpCG183D/AmpDH157Y) was increased eightfold (MIC = 2 mg/L). A double reverted PaR isolate (PaR-AmpCPaS/AmpDPaS) was obtained with a MIC close to that of PaS (MIC = 1 mg/L) and considerably reduced compared with that of PaR (MIC = 2 mg/L versus 32 mg/L) (Table 1).",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),2,mg/L,Pseudomonas aeruginosa,PaR-AmpCPaS/AmpDPaS,NAN,double reverted PaR isolate,NAN,ceftolozane/tazobactam (C/T),MIC = 2 mg/L,"C/T MIC values of PAO1-AmpCG183D and PAO1-AmpDH157Y were identical to that of PAO1 (MIC = 0.25 mg/L), while that of the PAO1 double mutant (PAO1-AmpCG183D/AmpDH157Y) was increased eightfold (MIC = 2 mg/L). A double reverted PaR isolate (PaR-AmpCPaS/AmpDPaS) was obtained with a MIC close to that of PaS (MIC = 1 mg/L) and considerably reduced compared with that of PaR (MIC = 2 mg/L versus 32 mg/L) (Table 1).",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),32,mg/L,Pseudomonas aeruginosa,PaR,NAN,NAN,NAN,ceftolozane/tazobactam (C/T),32 mg/L,"C/T MIC values of PAO1-AmpCG183D and PAO1-AmpDH157Y were identical to that of PAO1 (MIC = 0.25 mg/L), while that of the PAO1 double mutant (PAO1-AmpCG183D/AmpDH157Y) was increased eightfold (MIC = 2 mg/L). A double reverted PaR isolate (PaR-AmpCPaS/AmpDPaS) was obtained with a MIC close to that of PaS (MIC = 1 mg/L) and considerably reduced compared with that of PaR (MIC = 2 mg/L versus 32 mg/L) (Table 1).",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),4,mg/L,Pseudomonas aeruginosa,PaS,NAN,resistant to IMI,NAN,imipenem (IMI),MIC of 4 mg/L,"Concerning IMI, the clinical isolate PaS was resistant to IMI with a MIC of 4 mg/L, whereas the clinical isolate PaR was susceptible with a MIC value of 1 mg/L.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),1,mg/L,Pseudomonas aeruginosa,PaR,NAN,susceptible,NAN,imipenem (IMI),MIC value of 1 mg/L,"Concerning IMI, the clinical isolate PaS was resistant to IMI with a MIC of 4 mg/L, whereas the clinical isolate PaR was susceptible with a MIC value of 1 mg/L.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),0.5,mg/L,Pseudomonas aeruginosa,PAO1,NAN,NAN,NAN,imipenem (IMI),0.5 mg/L,"Concerning IMI, the clinical isolate PaS was resistant to IMI with a MIC of 4 mg/L, whereas the clinical isolate PaR was susceptible with a MIC value of 1 mg/L. MICs of PAO1 and PAO1-AmpDH157Y to IMI were 0.5 mg/L.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),0.5,mg/L,Pseudomonas aeruginosa,PAO1-AmpDH157Y,NAN,AmpDH157Y mutation,NAN,imipenem (IMI),0.5 mg/L,"Concerning IMI, the clinical isolate PaS was resistant to IMI with a MIC of 4 mg/L, whereas the clinical isolate PaR was susceptible with a MIC value of 1 mg/L. MICs of PAO1 and PAO1-AmpDH157Y to IMI were 0.5 mg/L.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),0.125,mg/L,Pseudomonas aeruginosa,PAO1-AmpCG183D,NAN,AmpCG183D mutation,NAN,imipenem (IMI),0.125 mg/L,"Concerning IMI, the clinical isolate PaS was resistant to IMI with a MIC of 4 mg/L, whereas the clinical isolate PaR was susceptible with a MIC value of 1 mg/L. MICs of PAO1 and PAO1-AmpDH157Y to IMI were 0.5 mg/L. The values of MIC for strains carrying the AmpCG183D mutation (PAO1-AmpCG183D and PAO1-AmpCG183D/AmpDH157Y) were decreased to 0.125 mg/L (Table 2).",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,Minimum inhibitory concentration (MIC),0.125,mg/L,Pseudomonas aeruginosa,PAO1-AmpCG183D/AmpDH157Y,NAN,AmpCG183D mutation,NAN,imipenem (IMI),0.125 mg/L,"Concerning IMI, the clinical isolate PaS was resistant to IMI with a MIC of 4 mg/L, whereas the clinical isolate PaR was susceptible with a MIC value of 1 mg/L. MICs of PAO1 and PAO1-AmpDH157Y to IMI were 0.5 mg/L. The values of MIC for strains carrying the AmpCG183D mutation (PAO1-AmpCG183D and PAO1-AmpCG183D/AmpDH157Y) were decreased to 0.125 mg/L (Table 2).",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,"EC50,off",1.36,mg/L,Pseudomonas aeruginosa,PaS,NAN,NAN,NAN,ceftolozane/tazobactam (C/T),1.36 mg/L for PaS,"For clinical isolates, EC50,off value increased from 1.36 mg/L for PaS to 80.5 mg/L for PaR corresponding to a 59-fold difference and decreased to 6.77 mg/L for the double reverted PaR mutant.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,"EC50,off",80.5,mg/L,Pseudomonas aeruginosa,PaR,NAN,NAN,NAN,ceftolozane/tazobactam (C/T),80.5 mg/L for PaR,"For clinical isolates, EC50,off value increased from 1.36 mg/L for PaS to 80.5 mg/L for PaR corresponding to a 59-fold difference and decreased to 6.77 mg/L for the double reverted PaR mutant.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,"EC50,off",6.77,mg/L,Pseudomonas aeruginosa,PaR-AmpCPaS/AmpDPaS,NAN,double reverted PaR mutant,NAN,ceftolozane/tazobactam (C/T),6.77 mg/L,"For clinical isolates, EC50,off value increased from 1.36 mg/L for PaS to 80.5 mg/L for PaR corresponding to a 59-fold difference and decreased to 6.77 mg/L for the double reverted PaR mutant.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,"EC50,on",155,mg/L,Pseudomonas aeruginosa,PaS,NAN,NAN,NAN,ceftolozane/tazobactam (C/T),155 mg/L,"For clinical isolates, EC50,off value increased from 1.36 mg/L for PaS to 80.5 mg/L for PaR corresponding to a 59-fold difference and decreased to 6.77 mg/L for the double reverted PaR mutant. PaS EC50,on was estimated at 155 mg/L, that is 114-fold higher than EC50,off.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,"EC50,on",2.25,mg/L,Pseudomonas aeruginosa,PAO1-AmpCG183D,NAN,AmpCG183D mutation,NAN,imipenem (IMI),2.25 mg/L,"For PAO1 and mutant-derived strains, AmpCG183D and AmpDH157Y mutations alone induced greater acquired resistance than AmpCG183D/AmpDH157Y double mutation, with respectively a 4.5, 4.9, and 1.2-fold (with an overlap in 95% CI) increase in EC50,off compared to PAO1 (Table 2). In terms of adaptive resistance, PAO1 EC50,on was 60.3-fold higher than its corresponding EC50,off while it increased a lot less for the mutant-derived strains. Notably, strains with the AmpCG183D mutation have markedly lower EC50,on than PAO1 (2.25 and 3.29 mg/L vs 24.8 mg/L) and slightly lower than PAO1-AmpDH157Y (2.25 and 3.29 mg/L vs 7.68 mg/L). Other model parameters values for IMI are provided in Table S4.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,"EC50,on",3.29,mg/L,Pseudomonas aeruginosa,PAO1-AmpCG183D/AmpDH157Y,NAN,AmpCG183D mutation,NAN,imipenem (IMI),3.29 mg/L,"For PAO1 and mutant-derived strains, AmpCG183D and AmpDH157Y mutations alone induced greater acquired resistance than AmpCG183D/AmpDH157Y double mutation, with respectively a 4.5, 4.9, and 1.2-fold (with an overlap in 95% CI) increase in EC50,off compared to PAO1 (Table 2). In terms of adaptive resistance, PAO1 EC50,on was 60.3-fold higher than its corresponding EC50,off while it increased a lot less for the mutant-derived strains. Notably, strains with the AmpCG183D mutation have markedly lower EC50,on than PAO1 (2.25 and 3.29 mg/L vs 24.8 mg/L) and slightly lower than PAO1-AmpDH157Y (2.25 and 3.29 mg/L vs 7.68 mg/L). Other model parameters values for IMI are provided in Table S4.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,"EC50,on",24.8,mg/L,Pseudomonas aeruginosa,PAO1,NAN,NAN,NAN,imipenem (IMI),24.8 mg/L,"For PAO1 and mutant-derived strains, AmpCG183D and AmpDH157Y mutations alone induced greater acquired resistance than AmpCG183D/AmpDH157Y double mutation, with respectively a 4.5, 4.9, and 1.2-fold (with an overlap in 95% CI) increase in EC50,off compared to PAO1 (Table 2). In terms of adaptive resistance, PAO1 EC50,on was 60.3-fold higher than its corresponding EC50,off while it increased a lot less for the mutant-derived strains. Notably, strains with the AmpCG183D mutation have markedly lower EC50,on than PAO1 (2.25 and 3.29 mg/L vs 24.8 mg/L) and slightly lower than PAO1-AmpDH157Y (2.25 and 3.29 mg/L vs 7.68 mg/L). Other model parameters values for IMI are provided in Table S4.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
PMC10583683,"EC50,on",7.68,mg/L,Pseudomonas aeruginosa,PAO1-AmpDH157Y,NAN,AmpDH157Y mutation,NAN,imipenem (IMI),7.68 mg/L,"For PAO1 and mutant-derived strains, AmpCG183D and AmpDH157Y mutations alone induced greater acquired resistance than AmpCG183D/AmpDH157Y double mutation, with respectively a 4.5, 4.9, and 1.2-fold (with an overlap in 95% CI) increase in EC50,off compared to PAO1 (Table 2). In terms of adaptive resistance, PAO1 EC50,on was 60.3-fold higher than its corresponding EC50,off while it increased a lot less for the mutant-derived strains. Notably, strains with the AmpCG183D mutation have markedly lower EC50,on than PAO1 (2.25 and 3.29 mg/L vs 24.8 mg/L) and slightly lower than PAO1-AmpDH157Y (2.25 and 3.29 mg/L vs 7.68 mg/L). Other model parameters values for IMI are provided in Table S4.",Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling,"Deroche L, Aranzana-Climent V, Rozenholc A, Prouvensier L, Darnaud L, Grégoire N, Marchand S, Ploy M-C, François B, Couet W, Barraud O, Buyck JM. Characterization of Pseudomonas aeruginosa resistance to ceftolozane-tazobactam due to ampC and/or ampD mutations observed during treatment using semi-mechanistic PKPD modeling. Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0048023. doi: 10.1128/aac.00480-23. Epub 2023 Sep 11. PMID: 37695298; PMCID: PMC10583683.",,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,
